Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies
AbstractRecent studies have demonstrated that Janus kinase (JAK) plays a crucial role in signal transduction by directly affecting various cytokine receptors involved in inflammatory diseases such as atopic dermatitis (AD). Large-scale clinical trials on AD utilizing JAK inhibitors and biologic reag...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-07-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/25785826.2023.2214324 |
| _version_ | 1797767354478755840 |
|---|---|
| author | Toshiaki Kogame Gyohei Egawa Kenji Kabashima |
| author_facet | Toshiaki Kogame Gyohei Egawa Kenji Kabashima |
| author_sort | Toshiaki Kogame |
| collection | DOAJ |
| description | AbstractRecent studies have demonstrated that Janus kinase (JAK) plays a crucial role in signal transduction by directly affecting various cytokine receptors involved in inflammatory diseases such as atopic dermatitis (AD). Large-scale clinical trials on AD utilizing JAK inhibitors and biologic reagents, such as dupilumab, which targets the IL-4Rα receptor subunit of the Th2 cytokines IL-4 and IL-13, have yielded highly favorable results in comparison to traditional therapies. This indicates that therapeutic strategies based on molecular biology are efficacious in clinical settings. However, in September 2021, the U.S. Food and Drug Administration (FDA) indicated that tofacitinib, a JAK inhibitor, may carry various risks, including severe heart disease. Similar concerns have been raised for other JAK inhibitors, and further safety evaluations are underway. Thus, human biology involving JAKs appeared more complicated than we expected. In this article, we provide an overview of the molecular mechanisms of AD and examine the molecular targeting drugs for AD from the perspective of JAK-related biology. |
| first_indexed | 2024-03-12T20:38:30Z |
| format | Article |
| id | doaj.art-bdc856648a6840d4902b10c87c20431e |
| institution | Directory Open Access Journal |
| issn | 2578-5826 |
| language | English |
| last_indexed | 2024-03-12T20:38:30Z |
| publishDate | 2023-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Immunological Medicine |
| spelling | doaj.art-bdc856648a6840d4902b10c87c20431e2023-08-01T12:02:18ZengTaylor & Francis GroupImmunological Medicine2578-58262023-07-0146311212010.1080/25785826.2023.2214324Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategiesToshiaki Kogame0Gyohei Egawa1Kenji Kabashima2Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanDepartment of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanDepartment of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanAbstractRecent studies have demonstrated that Janus kinase (JAK) plays a crucial role in signal transduction by directly affecting various cytokine receptors involved in inflammatory diseases such as atopic dermatitis (AD). Large-scale clinical trials on AD utilizing JAK inhibitors and biologic reagents, such as dupilumab, which targets the IL-4Rα receptor subunit of the Th2 cytokines IL-4 and IL-13, have yielded highly favorable results in comparison to traditional therapies. This indicates that therapeutic strategies based on molecular biology are efficacious in clinical settings. However, in September 2021, the U.S. Food and Drug Administration (FDA) indicated that tofacitinib, a JAK inhibitor, may carry various risks, including severe heart disease. Similar concerns have been raised for other JAK inhibitors, and further safety evaluations are underway. Thus, human biology involving JAKs appeared more complicated than we expected. In this article, we provide an overview of the molecular mechanisms of AD and examine the molecular targeting drugs for AD from the perspective of JAK-related biology.https://www.tandfonline.com/doi/10.1080/25785826.2023.2214324Janus kinaseJAKatopic dermatitisJAK inhibitorJAKinibs |
| spellingShingle | Toshiaki Kogame Gyohei Egawa Kenji Kabashima Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies Immunological Medicine Janus kinase JAK atopic dermatitis JAK inhibitor JAKinibs |
| title | Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies |
| title_full | Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies |
| title_fullStr | Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies |
| title_full_unstemmed | Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies |
| title_short | Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies |
| title_sort | exploring the role of janus kinase jak in atopic dermatitis a review of molecular mechanisms and therapeutic strategies |
| topic | Janus kinase JAK atopic dermatitis JAK inhibitor JAKinibs |
| url | https://www.tandfonline.com/doi/10.1080/25785826.2023.2214324 |
| work_keys_str_mv | AT toshiakikogame exploringtheroleofjanuskinasejakinatopicdermatitisareviewofmolecularmechanismsandtherapeuticstrategies AT gyoheiegawa exploringtheroleofjanuskinasejakinatopicdermatitisareviewofmolecularmechanismsandtherapeuticstrategies AT kenjikabashima exploringtheroleofjanuskinasejakinatopicdermatitisareviewofmolecularmechanismsandtherapeuticstrategies |